{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:46:26Z","timestamp":1788281186209,"version":"build-2803163510"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>\n                      To assess the real-world impact of transitioning from the Dexcom G6\n                      <jats:sup>\u00ae<\/jats:sup>\n                      to G7\n                      <jats:sup>\u00ae<\/jats:sup>\n                      system in individuals with type 1 diabetes (T1D) using the Tandem t:slim X2\u2122 with Control-IQ\u2122. Primary outcomes included glycemic control changes, while secondary outcomes evaluated patient-reported outcomes (PROMs) and experiences (PREMs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A 3-month prospective, multicenter, observational study was conducted in individuals previously using Dexcom G6 and Control-IQ. Glycemic control was assessed via TIR\n                      <jats:sub>70\u2013180<\/jats:sub>\n                      and HbA\n                      <jats:sub>1c<\/jats:sub>\n                      . PREMs and PROMs were measured using validated questionnaires (Diabetes Quality of Life (DQoL), Type 1 Diabetes Life (ViDa1), Diabetes Distress Scale (DDS), and Diabetes Treatment Satisfaction Questionnaire). Statistical analyses were stratified by baseline TIR\n                      <jats:sub>70\u2013180<\/jats:sub>\n                      (&gt;70% vs &lt;70%) and sex.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study included 92 participants (mean age 38\u2009\u00b1\u200913\u2009years), with a baseline TIR\n                      <jats:sub>70\u2013180<\/jats:sub>\n                      of 76%\u2009\u00b1\u200910%. The overall TIR\n                      <jats:sub>70\u2212180<\/jats:sub>\n                      remained stable throughout the study. However, among participants with baseline TIR\n                      <jats:sub>70\u2013180<\/jats:sub>\n                      &lt;70%, a significant increase in TIR\n                      <jats:sub>70\u2212180<\/jats:sub>\n                      was observed, rising from 61%\u2009\u00b1\u20099% to 65%\u2009\u00b1\u20097% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.007). In consonance, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      levels showed a significant decline, from 7.3%\u2009\u00b1\u20090.9% to 7.0%\u2009\u00b1\u20090.6% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001). In addition, both glucose management indicator (GMI) and mean glucose levels significantly decreased over time, reflecting an overall improvement in glycemic control. These changes (GMI and glucose levels) were consistent across groups, with no significant differences based on baseline TIR\n                      <jats:sub>70-180<\/jats:sub>\n                      stratification. Quality of life and diabetes distress improved (DQoL, ViDa1, and DDS), especially in participants with lower baseline TIR\n                      <jats:sub>70-180<\/jats:sub>\n                      and in women. Some reported increased connectivity issues, but none led to treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      In Control-IQ users, the transition to G7\n                      <jats:sup>\u00ae<\/jats:sup>\n                      did not significantly impact glycemic control overall. However, a subgroup of patients with suboptimal baseline control (TIR\n                      <jats:sub>70\u2013180<\/jats:sub>\n                      &lt;70%) may benefit from this change, and enhanced quality of life and diabetes distress, especially in women.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420188251407515","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:43:58Z","timestamp":1768650238000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-9397","authenticated-orcid":false,"given":"L\u00eda","family":"Nattero-Ch\u00e1vez","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Carretera de Colmenar, Km 9.1, Madrid E-28034, Spain"},{"name":"Grupo de Investigaci\u00f3n en Diabetes, Obesidad y Reproducci\u00f3n Humana, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria &amp; Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM) &amp; Universidad de Alcal\u00e1, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Soledad","family":"Ruiz de Adana","sequence":"additional","affiliation":[{"name":"Endocrinology Department and Nutrition, Hospital Regional M\u00e1laga, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sim\u00f3-Servat","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism Research Unit, Vall d\u2019Hebron Research Institute Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Abad","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism Research Unit, Vall d\u2019Hebron Research Institute Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Quir\u00f3s","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitari Mutua de Terrassa, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Dur\u00e1n Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Getafe, Universidad Europea de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Quintero Tobar","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Diabetes, Obesidad y Reproducci\u00f3n Humana, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria &amp; Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas &amp; Universidad de Alcal\u00e1, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane","family":"Bayona","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ruiz Gracia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de la Calle de la Villa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Pic\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, M\u00e1laga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND, M\u00e1laga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0043"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S012"},{"key":"e_1_3_4_4_2","article-title":"7. Diabetes technology: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of care in diabetes-2025. Diabetes Care 2025; 48: S146\u2013S166.","journal-title":"Diabetes Care"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01486-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0558"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0341"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0143"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0011"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.4.517"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2013.11.036"},{"key":"e_1_3_4_13_2","first-page":"725","article-title":"The DCCT Research Group","volume":"11","author":"Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT)","year":"1988","unstructured":"Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988; 11: 725\u2013732.","journal-title":"Diabetes Care"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1575-0922(02)74482-3"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.00904"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.626"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008832821181"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15766"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0048"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241234072"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06366-x"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/ds23-0057"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0388"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1355"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01618-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0471"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0308"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251407515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188251407515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251407515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:18:17Z","timestamp":1781684297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188251407515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":26,"alternative-id":["10.1177\/20420188251407515"],"URL":"https:\/\/doi.org\/10.1177\/20420188251407515","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"article-number":"20420188251407515"}}